1. Park K, Goldstein I, Andry C, Siroky MB, Krane RJ, Azadzoi KM. Vasculogenic female sexual dysfunction: the hemodynamic basis for vaginal engorgement and clitoral erectile insufficiency. Int J Impot Res. 1997. 9:27–37.
Article
2. Goldstein I, Berman J. Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int J Impot res. 1998. 10:S84–S90.
3. Min KS, O'Conell L, Munarriz R, Huang YH, Choi S, Kim N, et al. Experimental models for the investigation of female sexual function and dysfunction. Int J Impot Res. 2001. 13:151–156.
Article
4. Berman JR, Berman L, Goldstein I. Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options. Urology. 1999. 54:385–391.
Article
5. Berman JR, Adhikari SP, Goldstein I. Anatomy and physiology of female sexual function and dysfunction. Eur Urol. 2000. 38:20–29.
Article
6. Guay A. Premenopausal and postmenopausal women with low libido have decreased testosterone and dehydroepiandrosterone-sulfate(DHEA-S) levels. Proceedings of female sexual function forum 3rd annual meeting. 2000. Boston: Female sexual function forum;56.
7. Tuiten A, Van HJ, Koppeschaar H, Bernaards C, Thijssen J, Verbaten R. Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry. 2000. 57:149–153.
Article
8. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, et al. A comparative study of safety and efficacy of continous low dose estradiol released from a vaginal ring compared with conjugated equine estrogen vaginal cream in the treatment of postmenopausal vaginal atrophy. Br J Obstet Gynaecol. 1996. 103:351–358.
9. Laan E, Everaerd W. Physiologic measure of vaginal vasocongestion. Int J Impot Res. 1998. 10:S107–S110.
10. Laan E, van Lunsen RHW, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric. 2001. 4:28–41.
Article
11. Bachmann G, Bancroft J, Braunstein G, Bruger H, Davis S, Dennerstein L, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril. 2002. 77(4):660–665.
Article
12. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab. 1999. 84:1527–1533.
13. Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, et al. Dehydroepiandrosterone(DHEA), DHEA sulfate, and aging: contribution of the DHEAge study to a sociobiomedical issue. Proc Natl Acad Sci. 2000. 97:4279–4284.
Article
14. Talalkoub L, Munarriz R, De E, Garcia S, Kim NN, Goldstine I, et al. Dehydroepiandrosterone(DHEA) treatment for female androgen insufficiency and sexual dysfunction: baseline and post-treatment biochemical data. Proceedings of Female Sexual Function Forum 4th Annual Meeting. 2001. Boston: Female Sexual Function Forum;123.
15. Kaplan SA, Rodolfo RB, Kohn IJ, Ikeguchi EF, Laor E, Te AE, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology. 1999. 53:481–486.
Article
16. Kegel AH. Sexual function of the pubococcygeal muscle. West J Surg Obstet Gynecol. 1952. 60:521–524.
17. Graber B. Female orgasm: role of pubococcygeus muscle. J Clin Psychiatry. 1979. 40:348–351.